We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.76%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$16.2B
AUM Growth
-$2.57B
Cap. Flow
+$150M
Cap. Flow %
0.93%
Top 10 Hldgs %
86.32%
Holding
116
New
17
Increased
25
Reduced
19
Closed
6

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$49.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$43.3M
3
KOD icon
Kodiak Sciences
KOD
+$31.6M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$27.5M
5
ALLK
Allakos
ALLK
+$27.1M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$60M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$48.2M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$10.4M
4
QURE icon
uniQure
QURE
+$9.23M
5
NXTC icon
NextCure
NXTC
+$8.45M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
76
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$3.08M 0.02%
250,000
– –
ORTX
77
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.06M 0.02%
40,570
– –
KRTX
78
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.02M 0.02%
+41,976
New +$3.59M
ARAV
79
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.8M 0.02%
486,333
+53,000
+12% +$475K
MRKR icon
80
Marker Therapeutics
MRKR
$19.3M
$2.79M 0.02%
147,020
-2,980
-2% -$75.9K
CRNX icon
81
Crinetics Pharmaceuticals
CRNX
$8.88B
$2.57M 0.02%
175,000
– –
LKFT
82
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$2.56M 0.02%
13,072
– –
XLRN
83
DELISTED
Acceleron Pharma
XLRN
$2.43M 0.01%
+27,000
New +$2.1M
GBT
84
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.4M 0.01%
+47,000
New +$3.15M
HARP
85
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.37M 0.01%
20,447
-982
-5% -$138K
MTNB icon
86
Matinas BioPharma
MTNB
$1.84M
$2.25M 0.01%
75,084
+22,437
+43% +$1.35M
APLT
87
DELISTED
Applied Therapeutics
APLT
$2.15M 0.01%
+65,934
New +$2.67M
VKTX icon
88
Viking Therapeutics
VKTX
$3.86B
$1.99M 0.01%
425,000
– –
BLUE
89
DELISTED
bluebird bio
BLUE
$1.84M 0.01%
3,088
– –
DNLI icon
90
Denali Therapeutics
DNLI
$3.78B
$1.84M 0.01%
+104,900
New +$2.19M
RCUS icon
91
Arcus Biosciences
RCUS
$3.31B
$1.69M 0.01%
121,534
– –
VYNE icon
92
VYNE Therapeutics
VYNE
$1.68M 0.01%
174
-20
-10% -$314K
NTLA icon
93
Intellia Therapeutics
NTLA
$1.5B
$1.57M 0.01%
128,538
– –
CYPH
94
Cypherpunk Technologies Inc
CYPH
$63.8M
$1.55M 0.01%
97,845
– –
IMTX icon
95
Immatics
IMTX
$1.19B
$1.53M 0.01%
+150,000
New +$1.58M
DRNA
96
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.5M 0.01%
+81,935
New +$1.59M
BLCM
97
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.17M 0.01%
249,123
-18,659
-7% -$200K
GTHX
98
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$970K 0.01%
88,026
-39,210
-31% -$732K
AUTL
99
Autolus Therapeutics
AUTL
$378M
$939K 0.01%
156,773
– –
GLMD icon
100
Galmed Pharmaceuticals
GLMD
$4.42M
$746K ﹤0.01%
1,198
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Baker Bros. Advisors held 116 positions worth $16.2B, down 14% from $18.8B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q1 2020 filing shows 17 new, 25 increased, 19 reduced and 6 closed positions. Its largest new stake was Adaptimmune Therapeutics: 3,690,307 shares worth $10M. The largest sale was Exact Sciences, an estimated $60M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2020 buy was Adaptimmune Therapeutics: 3,690,307 shares worth $10M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q1 2020, an estimated $49.3M increase.
  • Baker Bros. Advisors's biggest Q1 2020 reduction was Exact Sciences, cutting an estimated $60M.
  • Baker Bros. Advisors fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $48.2M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $16.2B portfolio in Q1 2020.
  • Baker Bros. Advisors opened 17 new positions and closed 6 in Q1 2020.
  • Baker Bros. Advisors's portfolio value fell 14% quarter-over-quarter to $16.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.